Pharmacy

Your Article Summary

See Latest Articles

Caspofungin for the treatment of candidaemia in patients with haematological malignancies
Clinical Microbiology and Infection, 06/29/09

Pagano L et al. - In a study to evaluate the efficacy of caspofungin in neutropenic pts with haematological malignancies (HM) and candidaemia, results suggest that treatment of candidaemia with caspofungin in neutropenic HM was efficacious, as it is in non-haematological subgroups.

• This study was prospectively conducted in 11 haematology divisions over a 2-yr period to evaluate the efficacy of caspofungin in 24 neutropenic pts with haematological malignancies (HM) and candidaemia.

• Pts had received chemotherapy for HM and were neutropenic (PNN < 0.5 x 109/L) for a median of 12 days (2–41) before candidaemia.
• Pts received caspofungin for a median duration of 12 days, obtaining a favourable overall response of 58%.
• At 30 days, 11 pts had died (46%); candidaemia was responsible for mortality in 6 pts (25%).

Today in Antimicrobials...keeping you current

Receive free subspecialty "5-minute updates" via email

Drugs for preventing malaria in travellers
Cochrane Reviews, 10/22/09

Comparison of Gentamicin and Mupirocin in the Prevention of Exit-Site Infection and Peritonitis in Peritoneal Dialysis
Advances in Peritoneal Dialysis, 10/20/09

Empirical Antimicrobial Therapy for Bloodstream Infection Due to Methicillin-Resistant Staphylococcus aureus: No Better than a Coin Toss
Infection Control and Hospital Epidemiology, 10/14/09

See All of Antimicrobials